Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | NPR3 | P17342 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787789 | 0.84 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7973606 | 0.84 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7973604 | 0.84 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21509312 | 0.75 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29444989 | 0.74 | ELANE (0.33) | CA1CA2CA7CA12CA14 | |
| SCHEMBL2870266 | 0.74 | CTSL (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8141807 | 0.74 | CTSL (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL977470 | 0.73 | SLC7A5 (0.38) | CA1CA2CA7CA12CA14 | |
| SCHEMBL16684109 | 0.73 | CA1 (0.37) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL27919760 | 0.73 | SLC7A5 (0.38) | CA1CA2CA7CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753744-B1 | PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7358258-B2 | Prodrugs of an ERK protein kinase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| EP-1753744-A1 | PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| US-20060058318-A1 | Prodrugs of an ERK protein kinase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-16 | — | — | US | disclosed |
| WO-2005113546-A1 | PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058318-A1 | Prodrugs of an ERK protein kinase inhibitor | MAP3K20, MAP3K1, MAP3K2 | CTSK 994/4885CTSS 1705/4885CA1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.